Daily Brief Health Care: GE HealthCare Technologies , Revvity, Cardinal Health, Immix Biopharma Inc, Kaken Pharmaceutical, SanBio Co Ltd and more

• GE HealthCare has deepened its push into precision medicine with a strategic agreement to acquire icometrix, a Belgium-based firm specializing in AI-powered brain imaging analysis.
• The deal, announced in September 2025, highlights GE HealthCare’s increasing commitment to neurological diagnostics and advanced clinical decision support tools.
• Although the financial details remain undisclosed and the transaction is still subject to regulatory clearance, GEHC intends to fund the acquisition entirely with cash on hand.

• Revvity Inc.’s Q2 2025 results reflect steady performance amidst challenging market and regulatory conditions.
• Organic revenue growth of 3% was achieved, aligning with the company’s initial forecasts.
• Revenue reached $720 million, bolstered by strong performances, particularly in the Life Sciences segment, which saw 4% organic growth.

• Cardinal Health Inc. delivered robust financial results for the fourth quarter of fiscal year 2025, reflecting strong growth across its operating segments and strategic acquisitions that expanded its capabilities in specialty solutions.
• Overall, the company reported a 19% increase in operating earnings for the quarter and a 15% increase for the full fiscal year, demonstrating effective execution against strategic priorities.
• Positively, Cardinal Health’s Pharmaceutical and Specialty Solutions segment, the company’s largest, showcased robust demand, contributing significantly to the financial results.

Immix Biopharma has released a financing and business update, reinforcing its focus on advancing the development of lead CAR-T candidate NXC-201. The company has announced a private placement from Goose Capital amounting to $9.1m (gross proceeds). It was noted that this strategic investment was led by Dr Nancy T Chang, one of the founders of Goose Capital. Dr Chang is a highly respected biotech executive, having led the development of Xolair (omalizumab, for severe asthma), Trogarzo (ibalizumab-uiyk, for HIV) and Ebglyss (lebrikizumab-lbkz, for dermatitis) through to FDA approval and subsequent commercialisation, collectively generating over $5bn in sales to date. She is also the former CEO of Tanox, which was acquired by Genentech/Roche in 2007. We therefore view the investment as an encouraging recognition of the potential of NXC-201, in particular for the treatment of amyloid light chain amyloidosis (ALA), the lead indication being targeted. The proceeds should extend Immix’s cash runway beyond near-term operational needs.

• Kaken Pharmaceutical (4521 JP) witnessed 3% YoY revenue growth in 1QFY26 to ¥18.9B as overseas pharmaceutical and crop protection sales while domestic market remained under pressure.
• Kaken’s major drug Clenafin saw revenue drop 3% to ¥4.4B on patent cliff, while Ecclock helped drive revenue growing 18% YoY to ¥803M.
• Kaken reiterated FY26 guidance where it expects revenue to fall 6% YoY to ¥88 billion. No respite from immediate pangs in the form of drug price revision and generic competition.

• In 1H FY01/26, the company reported no operating revenue, with an operating loss of JPY1.9bn and R&D expenses increasing by 31.5% YoY.
• Non-operating expenses totaled JPY596mn, primarily due to foreign exchange losses and financing fees, leading to a recurring loss of JPY2.5bn.
• The company forecasts a FY01/26 operating loss of JPY3.9bn and a net loss of JPY4.0bn, influenced by manufacturing costs and foreign exchange losses.